A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media
Primary Purpose
Acute Otitis Media
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
cefdinir (Omnicef)
amoxicillin
Sponsored by
About this trial
This is an interventional treatment trial for Acute Otitis Media
Eligibility Criteria
Inclusion Criteria:
- Clinical diagnosis, documented by medical history and physical examination, is acute otitis media <=1 week
- Clinical signs and symptoms include >=1 of the following: ear pain; ear fullness, decreased hearing, or discharge from the external auditory canal (following acute perforation of the tympanic membrane).
- At least two of the following conditions are present in at least one ear: bulging tympanic membrane, which may have redness; loss of the normal light reflex and tympanic membrane landmarks and abnormal tympanic membrane mobility on biphasic pneumatic otoscopy, due to the presence of pus or fluid behind it and edema of the tympanic membrane.
- Have evidence of middle ear fluid demonstrated by acoustic reflect-tympometry.
- Generally in good health based on medical history, vital signs, physical exam, and historical laboratory results
Exclusion Criteria:
- Previous enrollment in this study.
- Enrollment in any other investigational study using unapproved products or unapproved doses, including investigational vaccines in the previous four weeks prior to study start.
- Hypersensitivity reactions to cefdinir, other cephalosporins, penicillins, other drugs, and/or sensitivity to multiple allergens.
- Presence of tympanostomy tubes or otitis externa at Evaluation 1.
- Systemic treatment with any anti-infective agent within 7 days (14 days for azithromycin) prior to Evaluation 1 or during the study.
- Treatment with a long-acting injectable antimicrobial agent (e.g., penicillin G benzathine) within 4 weeks prior to study drug administration.
- Concomitant infection, that requires additional antimicrobial therapy.
- Evidence of chronic, suppurative otitis media.
- Evidence of a physiologic, anatomic, or immunologic defect, which would interfere with resolution of this episode of acute otitis media.
- Presence of a disease, complicating factor (e.g., mastoiditis), or structural abnormality that would preclude evaluation of the subject's therapeutic response.
- Known, severe renal impairment (i.e., creatinine clearance < 30 mUmid1.73 m2).
- History of Augmentin-associated cholestatic jaundicehepatic dysfunction.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
1
2
Arm Description
Outcomes
Primary Outcome Measures
Clinical Cure Rate
Secondary Outcome Measures
Sustained Clinical Cure Rate
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00644943
Brief Title
A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media
Official Title
A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media
Study Type
Interventional
2. Study Status
Record Verification Date
March 2008
Overall Recruitment Status
Completed
Study Start Date
February 2003 (undefined)
Primary Completion Date
April 2003 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Abbott
4. Oversight
5. Study Description
Brief Summary
The primary objective is to compare the safety and efficacy of cefdinir oral suspension, 7 mg/kg/day ql2hrs for 5 days, to amoxicillin/clavulanate oral suspension 45 mg/kg/day (based on amoxicillin component), in divided doses, q12h for 10 days, in children between 6 months and 6 years of age, with AOM.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Otitis Media
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Masking
Investigator
Allocation
Randomized
Enrollment
425 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Title
2
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
cefdinir (Omnicef)
Other Intervention Name(s)
ABT-198, Omnicef, cefdinir
Intervention Description
oral suspension (7 mg/kg, ql2hr) for 5 days
Intervention Type
Drug
Intervention Name(s)
amoxicillin
Intervention Description
oral suspension (45 mg/kg/day, q l2 hours) for 10 days
Primary Outcome Measure Information:
Title
Clinical Cure Rate
Time Frame
9 days
Secondary Outcome Measure Information:
Title
Sustained Clinical Cure Rate
Time Frame
28 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
6 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinical diagnosis, documented by medical history and physical examination, is acute otitis media <=1 week
Clinical signs and symptoms include >=1 of the following: ear pain; ear fullness, decreased hearing, or discharge from the external auditory canal (following acute perforation of the tympanic membrane).
At least two of the following conditions are present in at least one ear: bulging tympanic membrane, which may have redness; loss of the normal light reflex and tympanic membrane landmarks and abnormal tympanic membrane mobility on biphasic pneumatic otoscopy, due to the presence of pus or fluid behind it and edema of the tympanic membrane.
Have evidence of middle ear fluid demonstrated by acoustic reflect-tympometry.
Generally in good health based on medical history, vital signs, physical exam, and historical laboratory results
Exclusion Criteria:
Previous enrollment in this study.
Enrollment in any other investigational study using unapproved products or unapproved doses, including investigational vaccines in the previous four weeks prior to study start.
Hypersensitivity reactions to cefdinir, other cephalosporins, penicillins, other drugs, and/or sensitivity to multiple allergens.
Presence of tympanostomy tubes or otitis externa at Evaluation 1.
Systemic treatment with any anti-infective agent within 7 days (14 days for azithromycin) prior to Evaluation 1 or during the study.
Treatment with a long-acting injectable antimicrobial agent (e.g., penicillin G benzathine) within 4 weeks prior to study drug administration.
Concomitant infection, that requires additional antimicrobial therapy.
Evidence of chronic, suppurative otitis media.
Evidence of a physiologic, anatomic, or immunologic defect, which would interfere with resolution of this episode of acute otitis media.
Presence of a disease, complicating factor (e.g., mastoiditis), or structural abnormality that would preclude evaluation of the subject's therapeutic response.
Known, severe renal impairment (i.e., creatinine clearance < 30 mUmid1.73 m2).
History of Augmentin-associated cholestatic jaundicehepatic dysfunction.
Facility Information:
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35211
Country
United States
City
Montgomery
State/Province
Alabama
ZIP/Postal Code
36116
Country
United States
City
Ozark
State/Province
Alabama
ZIP/Postal Code
36360
Country
United States
City
Mesa
State/Province
Arizona
ZIP/Postal Code
85201
Country
United States
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85251
Country
United States
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72211
Country
United States
City
Clovis
State/Province
California
ZIP/Postal Code
93612
Country
United States
City
Fresno
State/Province
California
ZIP/Postal Code
93270
Country
United States
City
Longmont
State/Province
Colorado
ZIP/Postal Code
80501
Country
United States
City
Fairfield
State/Province
Connecticut
ZIP/Postal Code
06430
Country
United States
City
Marietta
State/Province
Georgia
ZIP/Postal Code
30062
Country
United States
City
Stone Mountain
State/Province
Georgia
ZIP/Postal Code
30087
Country
United States
City
Bardstown
State/Province
Kentucky
ZIP/Postal Code
40004
Country
United States
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40207
Country
United States
City
Owensboro
State/Province
Kentucky
ZIP/Postal Code
42301
Country
United States
City
Ruston
State/Province
Louisiana
ZIP/Postal Code
71270
Country
United States
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71105
Country
United States
City
Kalamazoo
State/Province
Michigan
ZIP/Postal Code
49008
Country
United States
City
Richland
State/Province
Michigan
ZIP/Postal Code
49083
Country
United States
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68178
Country
United States
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89104
Country
United States
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43205
Country
United States
City
Medford
State/Province
Oregon
ZIP/Postal Code
97504
Country
United States
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15241
Country
United States
City
Sellersville
State/Province
Pennsylvania
ZIP/Postal Code
18960
Country
United States
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29403
Country
United States
City
Austin
State/Province
Texas
ZIP/Postal Code
78758
Country
United States
City
Lake Jackson
State/Province
Texas
ZIP/Postal Code
77566
Country
United States
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84109
Country
United States
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84121
Country
United States
City
West Jordan
State/Province
Utah
ZIP/Postal Code
84084
Country
United States
City
Vienna
State/Province
Virginia
ZIP/Postal Code
22180
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media
We'll reach out to this number within 24 hrs